First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.

MLA

Chen, Xiaofeng, et al. “First-Line Camrelizumab (a PD-1 Inhibitor) plus Apatinib (an VEGFR-2 Inhibitor) and Chemotherapy for Advanced Gastric Cancer (SPACE): A Phase 1 Study.” Signal Transduction & Targeted Therapy, vol. 9, no. 1, Mar. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1038/s41392-024-01773-9.

APA

Chen, X., Xu, H., Chen, X., Xu, T., Tian, Y., Wang, D., Guo, F., Wang, K., Jin, G., Li, X., Wang, R., Li, F., Ding, Y., Tang, J., Fang, Y., Zhao, J., Liu, L., Ma, L., Meng, L., & Hou, Z. (2024). First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study. Signal Transduction & Targeted Therapy, 9(1), 1–8. https://doi.org/10.1038/s41392-024-01773-9

Chicago

Chen, Xiaofeng, Hao Xu, Xiaobing Chen, Tongpeng Xu, Yitong Tian, Deqiang Wang, Fen Guo, et al. 2024. “First-Line Camrelizumab (a PD-1 Inhibitor) plus Apatinib (an VEGFR-2 Inhibitor) and Chemotherapy for Advanced Gastric Cancer (SPACE): A Phase 1 Study.” Signal Transduction & Targeted Therapy 9 (1): 1–8. doi:10.1038/s41392-024-01773-9.